Compare Stocks: ACLX, INCY, BNTX, and UTHR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACLX Arcellx	$115.07	$114.67	$47.86 ▼ $115.13	$6.73B	0.25	1.50 million shs	14.67 million shs
BNTX BioNTech	$96.73 +0.3%	$97.00	$79.52 ▼ $124.00	$24.46B	1.29	1.11 million shs	1.18 million shs
INCY Incyte	$121.46 -1.5%	$121.70	$81.09 ▼ $132.60	$24.62B	0.77	1.72 million shs	1.42 million shs
UTHR United Therapeutics	$497.11 -1.3%	$522.08	$396.12 ▼ $609.35	$21.32B	0.56	494,315 shs	359,357 shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACLX Arcellx	0.00%	0.00%	0.00%	0.00%	+58.26%
BNTX BioNTech	-1.76%	-6.30%	+3.88%	+6.47%	-4.55%
INCY Incyte	-2.17%	-3.69%	+1.83%	+13.59%	+42.93%
UTHR United Therapeutics	-0.58%	+2.78%	-2.26%	-7.71%	+27.08%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACLX Arcellx	$115.07	$114.67	$47.86 ▼ $115.13	$6.73B	0.25	1.50 million shs	14.67 million shs
BNTX BioNTech	$96.73 +0.3%	$97.00	$79.52 ▼ $124.00	$24.46B	1.29	1.11 million shs	1.18 million shs
INCY Incyte	$121.46 -1.5%	$121.70	$81.09 ▼ $132.60	$24.62B	0.77	1.72 million shs	1.42 million shs
UTHR United Therapeutics	$497.11 -1.3%	$522.08	$396.12 ▼ $609.35	$21.32B	0.56	494,315 shs	359,357 shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACLX Arcellx	0.00%	0.00%	0.00%	0.00%	+58.26%
BNTX BioNTech	-1.76%	-6.30%	+3.88%	+6.47%	-4.55%
INCY Incyte	-2.17%	-3.69%	+1.83%	+13.59%	+42.93%
UTHR United Therapeutics	-0.58%	+2.78%	-2.26%	-7.71%	+27.08%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACLX Arcellx	2.06	Hold	$110.36	-4.10% Downside
BNTX BioNTech	2.68	Moderate Buy	$126.00	29.63% Upside
INCY Incyte	2.52	Moderate Buy	$124.05	1.44% Upside
UTHR United Therapeutics	2.85	Moderate Buy	$646.00	29.67% Upside

Current Analyst Ratings Breakdown

Latest ACLX, INCY, BNTX, and UTHR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/11/2026	INCY Incyte	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
9/8/2026	BNTX BioNTech	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform	$128.00 ➝ $105.00
9/1/2026	INCY Incyte	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Perform
8/31/2026	BNTX BioNTech	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$142.00 ➝ $136.00
8/27/2026	UTHR United Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B) ➝ Buy (B-)
8/24/2026	INCY Incyte	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/20/2026	INCY Incyte	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/20/2026	INCY Incyte	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$152.00
8/20/2026	INCY Incyte	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$150.00
8/17/2026	INCY Incyte	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$110.00 ➝ $130.00
8/13/2026	UTHR United Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Buy (B-) ➝ Buy (B)

(Data available from 9/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACLX Arcellx	$22.29M	301.95	N/A	N/A	$6.96 per share	16.53
BNTX BioNTech	$3.25B	7.57	$1.32 per share	73.50	$96.59 per share	1.01
INCY Incyte	$5.14B	4.82	$6.00 per share	20.39	$26.32 per share	4.65
UTHR United Therapeutics	$3.15B	6.77	$32.43 per share	15.36	$164.81 per share	3.02

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACLX Arcellx	-$228.93M	-$4.07	N/A	N/A	N/A	-1,027.26%	-55.42%	-36.24%	N/A
BNTX BioNTech	-$1.29B	-$7.83	N/A	N/A	N/A	-63.54%	-6.86%	-6.00%	11/3/2026 (Estimated)
INCY Incyte	$1.29B	$7.85	15.56	15.42	3.66	27.71%	29.93%	22.88%	10/27/2026 (Estimated)
UTHR United Therapeutics	$1.33B	$27.95	17.83	16.79	2.53	41.56%	20.18%	17.98%	11/4/2026 (Estimated)

Latest ACLX, INCY, BNTX, and UTHR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2026	Q2 2026	UTHR United Therapeutics	$6.86	$7.27	+$0.41	$7.27	$804.65 million	$783.30 million
8/4/2026	Q2 2026	BNTX BioNTech	-$2.3983	-$2.5340	-$0.1357	-$3.70	$180.18 million	$122.31 million
7/28/2026	Q2 2026	INCY Incyte	$2.15	$3.09	+$0.94	$2.81	$1.50 billion	$1.67 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACLX Arcellx	N/A	N/A	N/A	N/A	N/A
BNTX BioNTech	N/A	N/A	N/A	N/A	N/A
INCY Incyte	N/A	N/A	N/A	N/A	N/A
UTHR United Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACLX Arcellx	N/A	4.44	4.44
BNTX BioNTech	0.01	7.85	7.80
INCY Incyte	N/A	4.59	4.51
UTHR United Therapeutics	N/A	5.73	5.41

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACLX Arcellx	96.03%
BNTX BioNTech	15.52%
INCY Incyte	96.97%
UTHR United Therapeutics	94.08%

Insider Ownership

Company	Insider Ownership
ACLX Arcellx	8.35%
BNTX BioNTech	19.20%
INCY Incyte	16.20%
UTHR United Therapeutics	8.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACLX Arcellx	80	58.48 million	53.60 million	Optionable
BNTX BioNTech	7,807	252.88 million	204.33 million	Optionable
INCY Incyte	2,844	202.70 million	169.86 million	Optionable
UTHR United Therapeutics	1,400	42.89 million	39.20 million	Optionable

ACLX, INCY, BNTX, and UTHR Headlines

Recent News About These Companies

United Therapeutics (NASDAQ:UTHR) CEO Sells 9,500 Shares

28 minutes ago | marketbeat.com

Analysts Offer Insights on Healthcare Companies: Vor Biopharma (VOR), United Therapeutics (UTHR) and Spyre Therapeutics (SYRE)

September 11 at 2:45 AM | theglobeandmail.com

United Therapeutics (UTHR) Sets $477.6 Million Buyback. Can Pipeline Funding Keep Pace?

September 10 at 9:31 PM | insidermonkey.com

United Therapeutics Corporation $UTHR Holdings Decreased by Krensavage Asset Management LLC

September 10 at 6:07 AM | marketbeat.com

Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells 9,500 Shares of Stock

September 10 at 5:07 AM | insidertrades.com

Amundi Acquires 71,495 Shares of United Therapeutics Corporation $UTHR

September 10 at 3:20 AM | marketbeat.com

United Therapeutics : une dirigeante cède des actions pour un montant de 4 740 795 dollars, selon une déclaration à la SEC

September 9 at 6:44 PM | zonebourse.comZ

Therapeutics Stocks Q2 Teardown: United Therapeutics (NASDAQ:UTHR) Vs The Rest

September 9 at 6:44 PM | finance.yahoo.com

United Therapeutics Corporation (UTHR) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript

September 9 at 6:44 PM | seekingalpha.com

United Therapeutics (NASDAQ:UTHR) CEO Sells 9,500 Shares of Stock

September 9 at 5:06 PM | marketbeat.com

United Therapeutics enters $477.6M accelerated share repurchase

September 8 at 5:39 PM | msn.com

United Therapeutics Announces New Accelerated Share Repurchase

September 8 at 5:30 PM | tipranks.com

Martine Rothblatt Sells 9,500 Shares of United Therapeutics (NASDAQ:UTHR) Stock

September 8 at 5:07 PM | marketbeat.com

United Therapeutics Corporation (UTHR) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

September 8 at 3:00 PM | seekingalpha.com

United Therapeutics Corporation Announces Accelerated Share Repurchase Agreement for Remainder of $2.0 Billion Authorization

September 8 at 7:32 AM | markets.ft.com

California State Teachers Retirement System Grows Stake in United Therapeutics Corporation $UTHR

September 8 at 4:24 AM | marketbeat.com

Hsbc Holdings PLC Raises Stake in United Therapeutics Corporation $UTHR

September 8 at 3:52 AM | marketbeat.com

16,970 Shares in United Therapeutics Corporation $UTHR Purchased by Nykredit A S

September 6, 2026 | marketbeat.com

United Therapeutics (NASDAQ:UTHR) CEO Sells $4,687,870.00 in Stock

September 6, 2026 | americanbankingnews.com

Insider Selling: United Therapeutics (NASDAQ:UTHR) EVP Sells $4,000,849.00 in Stock

September 6, 2026 | americanbankingnews.com

Odyssean LLC Purchases 2,358 Shares of United Therapeutics Corporation $UTHR

September 5, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACLX, INCY, BNTX, and UTHR Company Descriptions

Arcellx NASDAQ:ACLX

Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

BioNTech NASDAQ:BNTX

$96.73 +0.33 (+0.34%)

Closing price 04:00 PM Eastern

Extended Trading

$97.10 +0.37 (+0.38%)

As of 05:32 PM Eastern

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

Incyte NASDAQ:INCY

$121.46 -1.82 (-1.48%)

Closing price 04:00 PM Eastern

Extended Trading

$120.62 -0.83 (-0.69%)

As of 05:23 PM Eastern

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

United Therapeutics NASDAQ:UTHR

$497.11 -6.75 (-1.34%)

Closing price 04:00 PM Eastern

Extended Trading

$501.91 +4.80 (+0.97%)

As of 05:33 PM Eastern

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ACLX, INCY, BNTX, and UTHR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ACLX, INCY, BNTX, and UTHR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ACLX, INCY, BNTX, and UTHR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACLX, INCY, BNTX, and UTHR Company Descriptions

Arcellx NASDAQ:ACLX

BioNTech NASDAQ:BNTX

Incyte NASDAQ:INCY

United Therapeutics NASDAQ:UTHR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ACLX, INCY, BNTX, and UTHR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ACLX, INCY, BNTX, and UTHR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ACLX, INCY, BNTX, and UTHR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACLX, INCY, BNTX, and UTHR Company Descriptions

Arcellx NASDAQ:ACLX

BioNTech NASDAQ:BNTX

Incyte NASDAQ:INCY

United Therapeutics NASDAQ:UTHR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools